H.C. Wainwright stated on Thursday that Sarepta Therapeutics’ (SRPT) recent divestiture in Arrowhead (ARWR) weakened its ...

SRPT rallies after Q2 earnings and revenue beat expectations as Elevidys deliveries resume following FDA clearance.

Investing.com - TD Cowen heeft zijn Hold-rating en koersdoel van $ 17,00 voor Sarepta Therapeutics (NASDAQ: SRPT) herbevestigd. De aandelen van het bedrijf zijn het afgelopen jaar met meer dan 85% ged ...

De FDA concludeerde dat het overlijden van een 8-jarige patiënt niet gerelateerd was aan Elevidys, waardoor leveringen aan ambulante DMD-patiënten konden worden hervat. Elke levering zal nu vergezeld ...

Sarepta Therapeutics ( ($SRPT) ) has shared an update. Sarepta Therapeutics announced a strategic restructuring and pipeline prioritization, ...

Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.

Sarepta Therapeutics (NasdaqGS:SRPT) Faces Shipment Suspension Amid Safety Update Sarepta Therapeutics (NasdaqGS:SRPT) recently provided updates that may have influenced its stock performance. The ...

Biotech company Sarepta Therapeutics (NASDAQ:SRPT) reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 80.2% year on year to $744.9 million. Its non-GAAP loss of $3.42 ...

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Shares of Sarepta Therapeutics ( NASDAQ: SRPT) rose on Wednesday after the market as it reported second quarter revenue and ...

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT Provided by PR Newswire Jul 2, 2025, 6:24:00 AM ...